What are the guidelines for treatment of chronic HCV infection in NS3 PI + PEG-IFN/ribavirin treatment-experienced genotype 1 patients without cirrhosis?

Updated: Oct 07, 2019
  • Author: Vinod K Dhawan, MD, FACP, FRCPC, FIDSA; Chief Editor: BS Anand, MD  more...
  • Print
Answer

HCV genotype 1 nonstructural protein 3 (NS3) protease inhibitor (eg, simeprevir) plus PEG-IFN/ribavirin treatment-experienced patients without cirrhosis

Recommended regimens

  • Daily fixed-dose combination of ledipasvir (90 mg)/sofosbuvir (400 mg) for 12 weeks
  • Daily fixed-dose combination of sofosbuvir (400 mg)/velpatasvir (100 mg) for 12 weeks
  • Daily fixed-dose combination of glecaprevir (300 mg)/pibrentasvir (120 mg) for 12 weeks

Alternative regimens

  • Daily fixed-dose combination of elbasvir (50 mg)/grazoprevir (100 mg) with weight-based ribavirin for 12 weeks for all genotype 1b patients, as well as genotype 1a patients without baseline NS5A RASs for elbasvir. Extend this treatment to 16 weeks for genotype 1a patients who have baseline NS5A RASs for elbasvir.

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!